glp 1 meds and dementia In New Trials, Ozempic's 'Miracle Drug' Image Takes a Hit Could diabetes and weight loss

Scrutiny increases in a good way: tighter guardrails on claims, stronger post-market QA, and fewer proprietary blends that promise too much

Although US in a non-invasive and practical method, it has low sensitivity for mild levels of steatosis and cannot be used for the distinction between NAFLD and NASH, without a concomitant liver biopsy

*Correspondence: Weihong Kuang, [email protected]

Gamble, J.-M., Chibrikov, E., Midodzi, W

doi:10.1073/pnas.0402760101

Rates of patients switching from AOM tirzepatide declined in the months following July 2025 and returned to near baseline levels by October, and growth in AOM tirzepatide prescribing rebounded after the initial decline